For example, scn1lab−/− mutants (a model of Dravet syndrome) have served as a screening platform and have pinpointed clemizole as a potential drug candidate for Dravet syndrome patients (Baraban et al., 2013), and more recently also for STXBP1 mutations carriers (Moog and Baraban, 2022). The gene discussed is STXBP1; the disease is Dravet syndrome.